icon-folder.gif   Conference Reports for NATAP  
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
Dual-Combination Therapy (NASH) Directed Against Lysyl Oxidase-Like-2 and Apoptosis Signal-Regulating Kinase 1 Potently Inhibits Fibrosis and Portal Hypertension in a New Mouse Model of PSC-Like Liver Disease/NASH
  Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Naoki Ikenaga,1 Susan Liu,1 Kahini Vaid,1 Zhen-Wei Peng,1 Andrew Greenstein,2 Dorothy French,2 Victoria Smith,2 Yury Popov1
1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; 2Gilead Sciences, Inc., Foster City, CA
GS-4997, an apoptosis signal-regulating kinase (ASK1) inhibitor, is currently being evaluated in a Phase 2 study of patients with NASH and moderate to severe liver fibrosis. Simtuzumab, an anti-lysyl oxidase-like-2 (LOXL2) antibody, is being evaluated for the treatment of NASH and PSC in ongoing Phase 2b trials.